Previous Close | 143.38 |
Open | 143.07 |
Bid | 135.45 x 1100 |
Ask | 136.00 x 1000 |
Day's Range | 131.39 - 144.77 |
52 Week Range | 119.01 - 497.49 |
Volume | |
Avg. Volume | 7,157,155 |
Market Cap | 55.243B |
Beta (5Y Monthly) | 1.54 |
PE Ratio (TTM) | 8.16 |
EPS (TTM) | 16.69 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 230.27 |
Here's why they picked Exelixis (NASDAQ: EXEL), Moderna (NASDAQ: MRNA), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Exelixis): If you're looking to hit a home run with an investment, it's important to look for a balance of a modest valuation and promising growth. One underrated stock that possesses all these features is cancer-fighting company Exelixis, which has a market cap of around $5.4 billion.
Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) are no longer big winners for investors. Let's first address the uncertainties for Moderna. There are questions about the high number of side effects of its experimental influenza vaccine.
Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.